In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Actelion partners orexin antagonist for insomnia with GSK

Executive Summary

Swiss biotech Actelion has licensed GlaxoSmithKline exclusive worldwide rights (outside Japan) to co-develop and co-promote its Phase III almorexant for primary insomnia plus additional indications. Almorexant, an orexin receptor antagonist, is an oral agent that can penetrate the blood-brain barrier.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies